Aclaris Therapeutics Ownership 2024 | Who Owns Aclaris Therapeutics Now?


OverviewForecastRevenueFinancialsChartTranscripts

Institutional Ownership

42.00%

Insider Ownership

2.54%

Retail Ownership

55.46%

Institutional Holders

51.00

Aclaris Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BML CAPITAL MANAGEMENT, LLC13.26%7.68%9,395,9348,742,8271338.65%11,650,958Mar 31, 2024
BLACKROCK INC.7.34%0.00%5,202,147-703,725-11.92%6,450,660Mar 31, 2024
VANGUARD GROUP INC6.96%0.00%4,929,775207,4184.39%6,112,921Mar 31, 2024
D. E. SHAW & CO., INC.4.63%0.00%3,282,9821,343,97269.31%4,070,898Mar 31, 2024
MILLENNIUM MANAGEMENT LLC4.62%0.00%3,273,492-205,869-5.92%4,059,130Mar 31, 2024
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC4.23%0.30%3,000,000-500,000-14.29%3,720,000Mar 31, 2024
ROCK SPRINGS CAPITAL MANAGEMENT LP3.89%0.09%2,753,495-245,000-8.17%3,414,334Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC3.01%0.01%2,135,367-216,040-9.19%2,646,000Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC2.36%0.00%1,673,400-73,032-4.18%2,075,000Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC2.21%0.00%1,565,054171,50612.31%1,940,845Mar 31, 2024
TWO SIGMA ADVISERS, LP2.05%0.00%1,451,10030,1002.12%1,799,364Mar 31, 2024
STATE STREET CORP1.89%0.00%1,338,439-50,000-3.60%1,659,664Mar 31, 2024
TWO SIGMA INVESTMENTS, LP1.88%0.00%1,329,616-133,845-9.15%1,648,724Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD1.71%0.00%1,212,260-467,645-27.84%1,503,202Mar 31, 2024
DEUTSCHE BANK AG\1.35%0.00%957,02122,9752.46%1,186,706Mar 31, 2024
CITADEL ADVISORS LLC1.31%0.00%930,003-4,458,786-82.74%1,153,203Mar 31, 2024
SAMSARA BIOCAPITAL, LLC0.98%0.13%696,171--863,252Mar 31, 2024
GSA CAPITAL PARTNERS LLP0.96%0.07%679,137-908,858-57.23%842,000Mar 31, 2024
FMR LLC0.95%0.00%671,8281,1140.17%833,067Mar 31, 2024
AQR CAPITAL MANAGEMENT LLC0.86%0.00%612,205612,205100.00%759,134Mar 31, 2024

Aclaris Therapeutics's largest institutional shareholder is BML CAPITAL MANAGEMENT, LLC, holding 13.26% of the company's total share outstanding, currently valued at $11.65M. The top 10 institutional shareholders own together 52.51% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BML CAPITAL MANAGEMENT, LLC13.26%7.68%9,395,9348,742,8271338.65%11,650,958Mar 31, 2024
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC4.23%0.30%3,000,000-500,000-14.29%3,720,000Mar 31, 2024
ACUITAS INVESTMENTS, LLC0.65%0.29%461,663461,663100.00%572,462Mar 31, 2024
AISLING CAPITAL MANAGEMENT LP0.61%0.18%434,455--538,724Mar 31, 2024
DEUTERIUM CAPITAL MANAGEMENT, LLC0.11%0.18%79,99379,993100.00%99,191Mar 31, 2024
SAMSARA BIOCAPITAL, LLC0.98%0.13%696,171--863,252Mar 31, 2024
ROCK SPRINGS CAPITAL MANAGEMENT LP3.89%0.09%2,753,495-245,000-8.17%3,414,334Mar 31, 2024
PALO ALTO INVESTORS LP0.80%0.08%569,832569,832100.00%706,592Mar 31, 2024
GSA CAPITAL PARTNERS LLP0.96%0.07%679,137-908,858-57.23%842,000Mar 31, 2024
XTX TOPCO LTD0.17%0.02%123,100-255,200-67.46%152,644Mar 31, 2024
MARQUETTE ASSET MANAGEMENT, LLC0.12%0.02%83,97983,979100.00%104,134Mar 31, 2024
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.0.37%0.01%264,377--327,827Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC3.01%0.01%2,135,367-216,040-9.19%2,646,000Mar 31, 2024
FNY INVESTMENT ADVISERS, LLC0.01%0.01%10,00010,000100.00%12,000Mar 31, 2024
BBR PARTNERS, LLC0.08%0.01%60,00060,000100.00%74,400Mar 31, 2024
HARBOR CAPITAL ADVISORS, INC.0.04%0.01%30,98430,984100.00%38,000Mar 31, 2024
TWO SIGMA ADVISERS, LP2.05%0.00%1,451,10030,1002.12%1,799,364Mar 31, 2024
TWO SIGMA INVESTMENTS, LP1.88%0.00%1,329,616-133,845-9.15%1,648,724Mar 31, 2024
D. E. SHAW & CO., INC.4.63%0.00%3,282,9821,343,97269.31%4,070,898Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC2.36%0.00%1,673,400-73,032-4.18%2,075,000Mar 31, 2024

The largest Aclaris Therapeutics shareholder by % of total assets is BML CAPITAL MANAGEMENT, LLC. The company owns 9.40M shares of Aclaris Therapeutics (ACRS), representing 7.68% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BML CAPITAL MANAGEMENT, LLC13.26%7.68%9,395,9348,742,8271338.65%11,650,958Mar 31, 2024
D. E. SHAW & CO., INC.4.63%0.00%3,282,9821,343,97269.31%4,070,898Mar 31, 2024
AQR CAPITAL MANAGEMENT LLC0.86%0.00%612,205612,205100.00%759,134Mar 31, 2024
PALO ALTO INVESTORS LP0.80%0.08%569,832569,832100.00%706,592Mar 31, 2024
ACUITAS INVESTMENTS, LLC0.65%0.29%461,663461,663100.00%572,462Mar 31, 2024
VANGUARD GROUP INC6.96%0.00%4,929,775207,4184.39%6,112,921Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC2.21%0.00%1,565,054171,50612.31%1,940,845Mar 31, 2024
MAN GROUP PLC0.35%0.00%247,675146,395144.54%307,117Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.17%-123,460123,460100.00%153,090Mar 31, 2024
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.0.14%0.00%100,773100,773100.00%124,959Mar 31, 2024
MARQUETTE ASSET MANAGEMENT, LLC0.12%0.02%83,97983,979100.00%104,134Mar 31, 2024
DEUTERIUM CAPITAL MANAGEMENT, LLC0.11%0.18%79,99379,993100.00%99,191Mar 31, 2024
JANE STREET GROUP, LLC0.47%0.00%331,74072,35627.90%411,358Mar 31, 2024
STRS OHIO0.37%0.00%264,70071,70037.15%328,000Mar 31, 2024
RUSSELL INVESTMENTS GROUP, LTD.0.09%0.00%62,77261,6025265.13%77,837Mar 31, 2024
BBR PARTNERS, LLC0.08%0.01%60,00060,000100.00%74,400Mar 31, 2024
GROUP ONE TRADING, L.P.0.19%0.00%133,83156,63073.35%165,950Mar 31, 2024
VERITION FUND MANAGEMENT LLC0.08%0.00%53,83553,835100.00%66,755Mar 31, 2024
UBS GROUP AG0.10%-70,40150,777258.75%87,297Mar 31, 2024
HSBC HOLDINGS PLC0.07%-46,35846,358100.00%57,484Mar 31, 2024

As of Mar 31 2024, Aclaris Therapeutics's largest institutional buyer is BML CAPITAL MANAGEMENT, LLC. The company purchased 8.74M stocks of ACRS, valued at $11.65M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
CITADEL ADVISORS LLC1.31%0.00%930,003-4,458,786-82.74%1,153,203Mar 31, 2024
VELAN CAPITAL INVESTMENT MANAGEMENT LP----1,761,595-100.00%-Mar 31, 2024
TANG CAPITAL MANAGEMENT LLC----1,753,335-100.00%-Mar 31, 2024
MONACO ASSET MANAGEMENT SAM----979,399-100.00%-Mar 31, 2024
GSA CAPITAL PARTNERS LLP0.96%0.07%679,137-908,858-57.23%842,000Mar 31, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC----748,775-100.00%-Mar 31, 2024
BLACKROCK INC.7.34%0.00%5,202,147-703,725-11.92%6,450,660Mar 31, 2024
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC4.23%0.30%3,000,000-500,000-14.29%3,720,000Mar 31, 2024
CITIGROUP INC0.02%-12,335-495,173-97.57%15,295Mar 31, 2024
MORGAN STANLEY0.69%-491,666-484,213-49.62%609,665Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD1.71%0.00%1,212,260-467,645-27.84%1,503,202Mar 31, 2024
CHECKPOINT CAPITAL L.P.----453,614-100.00%-Mar 31, 2024
GOLDMAN SACHS GROUP INC0.21%-145,812-375,068-72.01%180,807Mar 31, 2024
NUVEEN ASSET MANAGEMENT, LLC0.24%0.00%166,656-273,245-62.12%206,653Mar 31, 2024
XTX TOPCO LTD0.17%0.02%123,100-255,200-67.46%152,644Mar 31, 2024
ROCK SPRINGS CAPITAL MANAGEMENT LP3.89%0.09%2,753,495-245,000-8.17%3,414,334Mar 31, 2024
ACADIAN ASSET MANAGEMENT LLC3.01%0.01%2,135,367-216,040-9.19%2,646,000Mar 31, 2024
MILLENNIUM MANAGEMENT LLC4.62%0.00%3,273,492-205,869-5.92%4,059,130Mar 31, 2024
CREDIT SUISSE AG/----135,629-100.00%-Mar 31, 2024
TWO SIGMA INVESTMENTS, LP1.88%0.00%1,329,616-133,845-9.15%1,648,724Mar 31, 2024

As of Mar 31 2024, Aclaris Therapeutics's biggest institutional seller is CITADEL ADVISORS LLC. The company sold -4.46M shares of ACRS, valued at $1.15M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
AQR CAPITAL MANAGEMENT LLC0.86%0.00%612,205612,205100.00%759,134Mar 31, 2024
PALO ALTO INVESTORS LP0.80%0.08%569,832569,832100.00%706,592Mar 31, 2024
ACUITAS INVESTMENTS, LLC0.65%0.29%461,663461,663100.00%572,462Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.17%-123,460123,460100.00%153,090Mar 31, 2024
MARQUETTE ASSET MANAGEMENT, LLC0.12%0.02%83,97983,979100.00%104,134Mar 31, 2024
DEUTERIUM CAPITAL MANAGEMENT, LLC0.11%0.18%79,99379,993100.00%99,191Mar 31, 2024
BBR PARTNERS, LLC0.08%0.01%60,00060,000100.00%74,400Mar 31, 2024
HARBOR CAPITAL ADVISORS, INC.0.04%0.01%30,98430,984100.00%38,000Mar 31, 2024
TWO SIGMA SECURITIES, LLC0.02%0.00%16,11416,114100.00%19,981Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.02%-15,70015,700100.00%19,468Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.02%-13,50013,500100.00%16,740Mar 31, 2024
FNY INVESTMENT ADVISERS, LLC0.01%0.01%10,00010,000100.00%12,000Mar 31, 2024
CORNERSTONE PLANNING GROUP LLC0.00%0.00%580580100.00%789Mar 31, 2024
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC--1414100.00%17Mar 31, 2024

Aclaris Therapeutics's largest new institutional shareholder by number of shares is AQR CAPITAL MANAGEMENT LLC, purchased 612.21K shares, valued at $759.13K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VELAN CAPITAL INVESTMENT MANAGEMENT LP----1,761,595-100.00%-Mar 31, 2024
TANG CAPITAL MANAGEMENT LLC----1,753,335-100.00%-Mar 31, 2024
MONACO ASSET MANAGEMENT SAM----979,399-100.00%-Mar 31, 2024
JACOBS LEVY EQUITY MANAGEMENT, INC----748,775-100.00%-Mar 31, 2024
CHECKPOINT CAPITAL L.P.----453,614-100.00%-Mar 31, 2024
CREDIT SUISSE AG/----135,629-100.00%-Mar 31, 2024
LION POINT CAPITAL, LP----115,898-100.00%-Mar 31, 2024
UBS ASSET MANAGEMENT AMERICAS INC----113,601-100.00%-Mar 31, 2024
SWISS NATIONAL BANK----108,900-100.00%-Mar 31, 2024
OCTAGON CAPITAL ADVISORS LP----100,000-100.00%-Mar 31, 2024
ZURCHER KANTONALBANK (ZURICH CANTONALBANK)----43,784-100.00%-Mar 31, 2024
CHICAGO PARTNERS INVESTMENT GROUP LLC----20,988-100.00%-Mar 31, 2024
JANUS HENDERSON GROUP PLC----20,300-100.00%-Mar 31, 2024
WEXFORD CAPITAL LP----20,000-100.00%-Mar 31, 2024
IKARIAN CAPITAL, LLC----19,482-100.00%-Mar 31, 2024
BAYESIAN CAPITAL MANAGEMENT, LP----17,800-100.00%-Mar 31, 2024
ARIZONA STATE RETIREMENT SYSTEM----13,853-100.00%-Mar 31, 2024
OCCUDO QUANTITATIVE STRATEGIES LP----13,504-100.00%-Mar 31, 2024
TEACHER RETIREMENT SYSTEM OF TEXAS----11,458-100.00%-Mar 31, 2024
SQUAREPOINT OPS LLC----10,378-100.00%-Mar 31, 2024
GREAT WEST LIFE ASSURANCE CO /CAN/----1,944-100.00%-Mar 31, 2024
LINDBROOK CAPITAL, LLC----383-100.00%-Mar 31, 2024
HUNTINGTON NATIONAL BANK----334-100.00%-Mar 31, 2024
ADVISORNET FINANCIAL, INC----100-100.00%-Mar 31, 2024
CAPTION MANAGEMENT, LLC----100-100.00%-Mar 31, 2024

Aclaris Therapeutics's largest sold out institutional shareholder by shares sold is VELAN CAPITAL INVESTMENT MANAGEMENT LP, sold -1.76M shares, valued at -, as of undefined.

Aclaris Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
HARTFORD HLS SERIES FUND II INC1.10%271,395--Dec 31, 2023
Humankind Benefit Corp0.23%5,2034,496635.93%Dec 31, 2023
VANGUARD VALLEY FORGE FUNDS0.09%44,964--Dec 31, 2023
VANGUARD HORIZON FUNDS0.07%1,413,0081,413,008-Dec 31, 2023
FIDELITY COMMONWEALTH TRUST0.06%185,411132,115247.89%Feb 29, 2024
BRIDGEWAY FUNDS INC0.05%132,900--Dec 29, 2023
Federated Hermes MDT Series0.04%89,846--Jan 31, 2024
BlackRock Advantage SMID Cap Fund, Inc.0.03%6,060--Dec 29, 2023
BNY Mellon Strategic Funds, Inc.0.03%60,889--Mar 31, 2024
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.02%10,759--Dec 31, 2023
T. Rowe Price Quantitative Management Funds, Inc.0.02%75,030--Dec 31, 2023
FIDELITY CAPITAL TRUST0.02%218,000--Jan 31, 2024
QUANTITATIVE MASTER SERIES LLC0.02%123,4788,0086.94%Dec 31, 2023
Gabelli Healthcare & WellnessRx Trust0.01%1,365--Dec 29, 2023
VANGUARD VARIABLE INSURANCE FUNDS0.01%447,911447,911-Dec 31, 2023
Nushares ETF Trust0.01%60,443--Jan 31, 2024
VANGUARD INDEX FUNDS0.01%3,554,692961,50237.08%Dec 31, 2023
INVESCO EXCHANGE-TRADED FUND TRUST0.01%627,784--Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND0.01%134,507--Dec 31, 2023
TIAA SEPARATE ACCOUNT VA 10.01%1,604--Dec 31, 2023
FIDELITY SELECT PORTFOLIOS0.01%435,589--Feb 29, 2024
VANGUARD EXPLORER FUND0.01%73,649--Jan 31, 2024
DEUTSCHE DWS VARIABLE SERIES II0.01%12,953--Dec 31, 2023
MML SERIES INVESTMENT FUND0.00%43,885--Dec 31, 2023
ALPS ETF Trust0.00%50,005--Feb 29, 2024
HARTFORD SERIES FUND INC0.00%140,818--Dec 31, 2023
Calvert Variable Products, Inc.0.00%6,900--Dec 31, 2023
T. Rowe Price Index Trust, Inc.0.00%46,190--Feb 29, 2024
AdvisorShares Trust0.00%6,110--Dec 29, 2023
JPMORGAN INSURANCE TRUST0.00%26,398-1,102-4.01%Mar 31, 2023
NORTHWESTERN MUTUAL SERIES FUND INC0.00%241,684--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%392,278-155,308-28.36%Feb 29, 2024
MAINSTAY VP FUNDS TRUST0.00%217,727--Dec 31, 2023
SCHWAB STRATEGIC TRUST0.00%258,412-22,511-8.01%Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%40,404--Dec 31, 2023
FIDELITY SECURITIES FUND0.00%108,150--Jan 31, 2024
Forethought Variable Insurance Trust0.00%4,994--Dec 29, 2023
GOLDMAN SACHS VARIABLE INSURANCE TRUST0.00%4,438--Dec 31, 2023
Fidelity Commonwealth Trust II0.00%6,735--Aug 31, 2023
HARTFORD MUTUAL FUNDS II INC0.00%161,450--Jan 31, 2024
FIDELITY ADVISOR SERIES I0.00%176,350-222-0.13%Feb 29, 2024
Voya VARIABLE PORTFOLIOS INC0.00%28,525--Dec 31, 2023
LORD ABBETT SECURITIES TRUST0.00%4,200--Jan 31, 2024
TIAA-CREF LIFE FUNDS0.00%2,437--Dec 31, 2023
VARIABLE INSURANCE PRODUCTS FUND III0.00%7,300--Dec 31, 2023
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%3,483--Dec 31, 2023
ADVISORS' INNER CIRCLE FUND0.00%9,954--Jan 31, 2024
Principal Exchange-Traded Funds0.00%8,922-1,375-13.35%Mar 31, 2024
VANGUARD WORLD FUND0.00%170,9131,2440.73%Feb 29, 2024
JOHN HANCOCK INVESTMENT TRUST0.00%51,862--Jan 31, 2024
Voya INVESTORS TRUST0.00%29,904--Dec 31, 2023
Meeder Funds0.00%2,383--Mar 31, 2024
SunAmerica Specialty Series0.00%256--Apr 30, 2021
SEASONS SERIES TRUST0.00%9,539--Dec 31, 2023
PFM Multi-Manager Series Trust0.00%300--Dec 31, 2023
Dimensional ETF Trust0.00%158,672--Jan 31, 2024
GPS Funds I0.00%1,831--Dec 31, 2023
VANGUARD QUANTITATIVE FUNDS0.00%3,104--Dec 31, 2023
Victory Portfolios II0.00%15,791--Dec 31, 2023
Guardian Variable Products Trust0.00%4,400--Dec 31, 2023
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%22,4372,70013.68%Dec 31, 2023
RUSSELL INVESTMENT CO0.00%77,122--Jan 31, 2024
VARIABLE INSURANCE PRODUCTS FUND II0.00%2,853-1,506-34.55%Dec 31, 2023
iSHARES TRUST0.00%3,421,348--Feb 29, 2024
Trust for Advised Portfolios0.00%3,223--Dec 31, 2023
EQ ADVISORS TRUST0.00%186,185-44,671-19.35%Dec 31, 2023
VANGUARD SCOTTSDALE FUNDS0.00%316,32937,43913.42%Feb 29, 2024
MASSMUTUAL SELECT FUNDS0.00%159,843--Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%155,201--Jan 31, 2024
RYDEX SERIES FUNDS0.00%633--Dec 31, 2023
LoCorr Investment Trust0.00%3,773--Mar 31, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%171,40138,97029.43%Dec 31, 2023
OHIO NATIONAL FUND INC0.00%2,837-7,879-73.53%Dec 31, 2023
Blackstone Alternative Investment Funds0.00%15,50013,900868.75%Dec 31, 2023
ProFunds0.00%99040669.52%Jan 31, 2024
VALIC Co I0.00%26,654-107-0.40%Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%10,417-595-5.40%Jan 31, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%10,643-7,445-41.16%Dec 31, 2023
RYDEX DYNAMIC FUNDS0.00%314--Dec 31, 2023
PENN SERIES FUNDS INC0.00%2,100--Dec 29, 2023
PROSHARES TRUST0.00%15,4691,98114.69%Feb 29, 2024
AMERICAN CENTURY ETF TRUST0.00%6,867--Feb 29, 2024
HARTFORD MUTUAL FUNDS INC/CT0.00%487,136--Jan 31, 2024
ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST0.00%3,143--Dec 31, 2023
GOLDMAN SACHS TRUST0.00%8,555--Feb 29, 2024
Goldman Sachs ETF Trust0.00%5,008--Feb 29, 2024
Guggenheim Active Allocation Fund0.00%299--Feb 29, 2024
Invesco Exchange-Traded Self-Indexed Fund Trust0.00%10,908--Feb 29, 2024
Direxion Shares ETF Trust0.00%6,514--Jan 31, 2024
MASTER INVESTMENT PORTFOLIO0.00%3,568--Dec 31, 2023
Legg Mason Global Asset Management Trust0.00%36,000--Jan 31, 2024
NORTHERN FUNDS0.00%34,190--Dec 29, 2023
RYDEX VARIABLE TRUST0.00%41--Dec 31, 2023
FIRST TRUST EXCHANGE-TRADED FUND0.00%272--Dec 31, 2023
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%57,200-22,473-28.21%Dec 31, 2023
MORGAN STANLEY PATHWAY FUNDS0.00%2,445--Feb 29, 2024
ADVANCED SERIES TRUST0.00%95,132--Dec 29, 2023
SUNAMERICA SERIES TRUST0.00%7,869-3,851-32.86%Jan 31, 2024
Brinker Capital Destinations Trust0.00%1,273--Feb 29, 2024
ALLSPRING MASTER TRUST0.00%1,282--Feb 29, 2024

Aclaris Therapeutics's largest mutual fund holder by % of total assets is "HARTFORD HLS SERIES FUND II INC", owning 271.39K shares, compromising 1.10% of its total assets.

Aclaris Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2451-51.43%
31 Dec, 23105-33.54%
30 Sep, 231587.48%
30 Jun, 23147-13.53%
31 Mar, 2317031.78%
31 Dec, 221294.03%
30 Sep, 2212410.71%
30 Jun, 221120.90%
31 Mar, 22111-17.78%
31 Dec, 211353.85%
30 Sep, 21130-3.70%
30 Jun, 2113532.35%
31 Mar, 2110222.89%
31 Dec, 208353.70%
30 Sep, 2054-6.90%
30 Jun, 2058-13.43%
31 Mar, 2067-10.67%
31 Dec, 1975-2.60%
30 Sep, 1977-6.10%
30 Jun, 1982-10.87%
31 Mar, 1992-4.17%
31 Dec, 189615.66%
30 Sep, 1883-10.75%
30 Jun, 1893-6.06%
31 Mar, 1899-1.98%
31 Dec, 17101-3.81%
30 Sep, 171050.96%
30 Jun, 17104-8.77%
31 Mar, 1711414.00%
31 Dec, 1610069.49%
30 Sep, 165922.92%
30 Jun, 164841.18%
31 Mar, 16343.03%
31 Dec, 1533-

As of 31 Mar 24, 51 institutions are holding Aclaris Therapeutics's shares, representing a decrease of -51.43% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2429,764,046-48.96%
31 Dec, 2358,316,923-16.63%
30 Sep, 2369,947,964-1.60%
30 Jun, 2371,082,847-0.70%
31 Mar, 2371,582,1718.58%
31 Dec, 2265,928,6753.75%
30 Sep, 2263,546,3380.44%
30 Jun, 2263,269,8426.58%
31 Mar, 2259,362,9425.96%
31 Dec, 2156,022,392-1.32%
30 Sep, 2156,773,1281.50%
30 Jun, 2155,933,55624.41%
31 Mar, 2144,958,31341.27%
31 Dec, 2031,823,50724.53%
30 Sep, 2025,554,120-10.21%
30 Jun, 2028,460,085-11.30%
31 Mar, 2032,087,3704.21%
31 Dec, 1930,791,1285.99%
30 Sep, 1929,051,072-18.28%
30 Jun, 1935,547,373-6.12%
31 Mar, 1937,865,881-3.06%
31 Dec, 1839,060,18431.69%
30 Sep, 1829,659,852-4.25%
30 Jun, 1830,976,2750.92%
31 Mar, 1830,693,5257.91%
31 Dec, 1728,444,690-0.20%
30 Sep, 1728,502,74611.30%
30 Jun, 1725,609,9475.04%
31 Mar, 1724,381,27914.19%
31 Dec, 1621,351,91037.66%
30 Sep, 1615,510,2430.75%
30 Jun, 1615,395,1545.41%
31 Mar, 1614,605,45041.96%
31 Dec, 1510,288,591-

Aclaris Therapeutics (ACRS) has 29.76M shares outstanding as of 31 Mar 24, down -48.96% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2442.00%0.62%
31 Dec, 2382.36%0.84%
30 Sep, 2399.03%0.88%
30 Jun, 23106.30%0.93%
31 Mar, 23107.04%1.10%
31 Dec, 2298.86%1.09%
30 Sep, 2295.31%1.04%
30 Jun, 2295.88%1.03%
31 Mar, 2296.63%1.15%
31 Dec, 2191.50%1.06%
30 Sep, 2192.74%0.86%
30 Jun, 21103.64%1.30%
31 Mar, 2189.31%1.68%
31 Dec, 2073.01%2.05%
30 Sep, 2059.70%1.31%
30 Jun, 2067.55%1.14%
31 Mar, 2077.10%1.39%
31 Dec, 1974.51%1.51%
30 Sep, 1970.23%0.95%
30 Jun, 1986.12%1.02%
31 Mar, 1991.80%0.90%
31 Dec, 18100.77%1.10%
30 Sep, 1895.73%0.96%
30 Jun, 18100.10%1.01%
31 Mar, 1899.38%1.17%
31 Dec, 1792.24%0.94%
30 Sep, 1798.85%1.07%
30 Jun, 1796.30%1.10%
31 Mar, 1793.48%1.12%
31 Dec, 1691.28%1.74%
30 Sep, 1672.42%1.30%
30 Jun, 1674.51%1.42%
31 Mar, 1672.41%2.18%
31 Dec, 1557.70%-

As of 31 Mar 24, Aclaris Therapeutics is held by 42.00% institutional shareholders, representing a 0.62% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 2428-54.10%
31 Dec, 2361-27.38%
30 Sep, 238423.53%
30 Jun, 2368-19.05%
31 Mar, 238440.00%
31 Dec, 2260-9.09%
30 Sep, 22668.20%
30 Jun, 226129.79%
31 Mar, 2247-39.74%
31 Dec, 217811.43%
30 Sep, 2170-22.22%
30 Jun, 219038.46%
31 Mar, 216544.44%
31 Dec, 2045164.71%
30 Sep, 2017-29.17%
30 Jun, 2024-14.29%
31 Mar, 2028-15.15%
31 Dec, 1933-2.94%
30 Sep, 1934-24.44%
30 Jun, 1945-10.00%
31 Mar, 1950-23.08%
31 Dec, 186575.68%
30 Sep, 1837-27.45%
30 Jun, 1851-16.39%
31 Mar, 18617.02%
31 Dec, 1757-12.31%
30 Sep, 1765-9.72%
30 Jun, 17721.41%
31 Mar, 1771-20.22%
31 Dec, 1689128.21%
30 Sep, 1639-2.50%
30 Jun, 164081.82%
31 Mar, 1622-33.33%
31 Dec, 1533-

28 institutional shareholders have increased their position in ACRS stock as of 31 Mar 24 compared to 61 in the previous quarter (a -54.10% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 2417-34.62%
31 Dec, 2326-27.78%
30 Sep, 2336-5.26%
30 Jun, 2338-9.52%
31 Mar, 234216.67%
31 Dec, 223644.00%
30 Sep, 2225-7.41%
30 Jun, 2227-38.64%
31 Mar, 224425.71%
31 Dec, 2135-5.41%
30 Sep, 213727.59%
30 Jun, 212916.00%
31 Mar, 212513.64%
31 Dec, 202210.00%
30 Sep, 2020-
30 Jun, 2020-13.04%
31 Mar, 2023-8.00%
31 Dec, 1925-7.41%
30 Sep, 1927-
30 Jun, 192712.50%
31 Mar, 192420.00%
31 Dec, 1820-25.93%
30 Sep, 1827-3.57%
30 Jun, 18283.70%
31 Mar, 1827-20.59%
31 Dec, 173430.77%
30 Sep, 172618.18%
30 Jun, 1722-33.33%
31 Mar, 1733371.43%
31 Dec, 167-30.00%
30 Sep, 1610100.00%
30 Jun, 165-16.67%
31 Mar, 166-
31 Dec, 15--

17 institutional shareholders have reduced their position in ACRS stock as of 31 Mar 24 compared to 26 in the previous quarter (a -34.62% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2451-51.43%29,764,046-48.96%42.00%0.62%28-54.10%17-34.62%
31 Dec, 23105-33.54%58,316,923-16.63%82.36%0.84%61-27.38%26-27.78%
30 Sep, 231587.48%69,947,964-1.60%99.03%0.88%8423.53%36-5.26%
30 Jun, 23147-13.53%71,082,847-0.70%106.30%0.93%68-19.05%38-9.52%
31 Mar, 2317031.78%71,582,1718.58%107.04%1.10%8440.00%4216.67%
31 Dec, 221294.03%65,928,6753.75%98.86%1.09%60-9.09%3644.00%
30 Sep, 2212410.71%63,546,3380.44%95.31%1.04%668.20%25-7.41%
30 Jun, 221120.90%63,269,8426.58%95.88%1.03%6129.79%27-38.64%
31 Mar, 22111-17.78%59,362,9425.96%96.63%1.15%47-39.74%4425.71%
31 Dec, 211353.85%56,022,392-1.32%91.50%1.06%7811.43%35-5.41%
30 Sep, 21130-3.70%56,773,1281.50%92.74%0.86%70-22.22%3727.59%
30 Jun, 2113532.35%55,933,55624.41%103.64%1.30%9038.46%2916.00%
31 Mar, 2110222.89%44,958,31341.27%89.31%1.68%6544.44%2513.64%
31 Dec, 208353.70%31,823,50724.53%73.01%2.05%45164.71%2210.00%
30 Sep, 2054-6.90%25,554,120-10.21%59.70%1.31%17-29.17%20-
30 Jun, 2058-13.43%28,460,085-11.30%67.55%1.14%24-14.29%20-13.04%
31 Mar, 2067-10.67%32,087,3704.21%77.10%1.39%28-15.15%23-8.00%
31 Dec, 1975-2.60%30,791,1285.99%74.51%1.51%33-2.94%25-7.41%
30 Sep, 1977-6.10%29,051,072-18.28%70.23%0.95%34-24.44%27-
30 Jun, 1982-10.87%35,547,373-6.12%86.12%1.02%45-10.00%2712.50%
31 Mar, 1992-4.17%37,865,881-3.06%91.80%0.90%50-23.08%2420.00%
31 Dec, 189615.66%39,060,18431.69%100.77%1.10%6575.68%20-25.93%
30 Sep, 1883-10.75%29,659,852-4.25%95.73%0.96%37-27.45%27-3.57%
30 Jun, 1893-6.06%30,976,2750.92%100.10%1.01%51-16.39%283.70%
31 Mar, 1899-1.98%30,693,5257.91%99.38%1.17%617.02%27-20.59%
31 Dec, 17101-3.81%28,444,690-0.20%92.24%0.94%57-12.31%3430.77%
30 Sep, 171050.96%28,502,74611.30%98.85%1.07%65-9.72%2618.18%
30 Jun, 17104-8.77%25,609,9475.04%96.30%1.10%721.41%22-33.33%
31 Mar, 1711414.00%24,381,27914.19%93.48%1.12%71-20.22%33371.43%
31 Dec, 1610069.49%21,351,91037.66%91.28%1.74%89128.21%7-30.00%
30 Sep, 165922.92%15,510,2430.75%72.42%1.30%39-2.50%10100.00%
30 Jun, 164841.18%15,395,1545.41%74.51%1.42%4081.82%5-16.67%
31 Mar, 16343.03%14,605,45041.96%72.41%2.18%22-33.33%6-
31 Dec, 1533-10,288,591-57.70%-33---

Aclaris Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOF-InKindSell2,784$1.26$3.51K1,292,371
May 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptSell9,467--113,600
Apr 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOF-InKindSell3,224$1.26$4.06K1,285,688
Apr 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptSell9,467--123,067
Mar 05, 2024Walker Nealdirector, officer Interim President and CEOF-InKindSell3,223$1.24$4.00K1,279,445
Mar 05, 2024Walker Nealdirector, officer Interim President and CEOM-ExemptSell9,466--132,534
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell3,531$1.24$4.38K186,783
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell3,183$1.24$3.95K177,814
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell14,569$1.24$18.07K170,072
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell50,000--50,000
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell10,925--21,850
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell12,500---
Mar 05, 2024Balthaser Kevinofficer Chief Financial OfficerF-InKindSell427$1.24$529.4823,983

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptBuy9,467--1,295,155
May 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOF-InKindSell2,784$1.26$3.51K1,292,371
May 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptSell9,467--113,600
Apr 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptBuy9,467--1,288,912
Apr 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOF-InKindSell3,224$1.26$4.06K1,285,688
Apr 03, 2024Walker Nealdirector, officer INTERIM PRESIDENT AND CEOM-ExemptSell9,467--123,067
Mar 05, 2024Walker Nealdirector, officer Interim President and CEOM-ExemptBuy9,466--1,282,668
Mar 05, 2024Walker Nealdirector, officer Interim President and CEOF-InKindSell3,223$1.24$4.00K1,279,445
Mar 05, 2024Walker Nealdirector, officer Interim President and CEOM-ExemptSell9,466--132,534
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptBuy12,500--190,314
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell3,531$1.24$4.38K186,783
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptBuy50,000--184,641
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptBuy10,925--180,997
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell3,183$1.24$3.95K177,814
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerF-InKindSell14,569$1.24$18.07K170,072
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell50,000--50,000
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell10,925--21,850
Mar 05, 2024Monahan Josephofficer Chief Scientific OfficerM-ExemptSell12,500---
Mar 05, 2024Balthaser Kevinofficer Chief Financial OfficerM-ExemptBuy1,500--24,410
Mar 05, 2024Balthaser Kevinofficer Chief Financial OfficerF-InKindSell427$1.24$529.4823,983

The last insider sell of Aclaris Therapeutics's stock was made by Walker Neal on May 03 2024, selling 2,784 shares at $1.26 per share (valued at $3.51K).

Aclaris Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20242450.00%
Q1 20242524104.17%
Q4 2023-1-
Q3 20235771.43%
Q2 20232712225.00%
Q1 2023253180.65%
Q4 2022-14-
Q3 20224--
Q2 20222513192.31%
Q1 20222420120.00%
Q4 20211250.00%
Q3 20212450.00%
Q2 2021244751.06%
Q1 2021212584.00%
Q4 20203650.00%
Q3 20203475.00%
Q2 20201814128.57%
Q1 20203523152.17%
Q4 201971258.33%
Q3 201922100.00%

2 total buy trades, and 4 total sell trades (buy/sell ratio of 0.50%) were made by Aclaris Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024---
Q1 20242--
Q4 2023-1-
Q3 202321200.00%
Q2 2023-1-
Q1 202321612.50%
Q4 2022-13-
Q3 2022---
Q2 2022-5-
Q1 2022-6-
Q4 2021---
Q3 2021-1-
Q2 2021-33-
Q1 2021---
Q4 2020---
Q3 2020---
Q2 2020---
Q1 2020---
Q4 2019---
Q3 2019---

As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Aclaris Therapeutics's stocks.

Aclaris Therapeutics Peer Ownership


TickerCompany
GTHGenetron Holdings Limited
QGENQiagen N.V.
SHCSotera Health Company
ICLRICON Public Limited Company
RDNTRadNet, Inc.
CSTLCastle Biosciences, Inc.
NEOGNeogen Corporation
PREPrenetics Global Limited
MEDPMedpace Holdings, Inc.
BDSXBiodesix, Inc.
OLKOlink Holding AB (publ)
IQVIQVIA Holdings Inc.
MYGNMyriad Genetics, Inc.

ACRS Ownership FAQ


Aclaris Therapeutics is owned by institutional shareholders (42.00%), insiders (2.54%), and public (55.46%). The largest institutional shareholder of Aclaris Therapeutics is BML CAPITAL MANAGEMENT, LLC (13.26% of total shares) and the top mutual fund owner is HARTFORD HLS SERIES FUND II INC (1.10% of total shares).

Aclaris Therapeutics's major institutional shareholders are BML CAPITAL MANAGEMENT, LLC, BLACKROCK INC., VANGUARD GROUP INC, D. E. SHAW & CO., INC., and MILLENNIUM MANAGEMENT LLC. The top five shareholders own together 36.81% of the company's share outstanding.

As of Mar 2024, there are 51 institutional shareholders of Aclaris Therapeutics.

BML CAPITAL MANAGEMENT, LLC owns 9.4M shares of Aclaris Therapeutics, representing 13.26% of the company's total shares outstanding, valued at $11.65M (as of Mar 2024).

As of Mar 2024, BLACKROCK INC holds 5.2M shares of Aclaris Therapeutics (ACRS), compromising 7.34% of the company, valued at $6.45M.

VANGUARD GROUP INC is the third largest holder of Aclaris Therapeutics. The company owns 4.93M of the company's shares outstanding (worth $6.11M).